The relevant Disclosure is attached
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Fortis Malar Hospitals announced its unaudited Q3 FY26 and 9M FY26 results (ended Dec 31, 2025), which were approved at a board meeting on Feb 6, 2026. The board also appointed Mr. Bidesh Chandra Paul as Whole-time Director & KMP for 3 years and re-appointed Ms. Shailaja Chandra as Independent Director for a second 5-year term. The auditor (BSR & Co. LLP) issued an unmodified review report but included a critical Emphasis of Matter on Note 5: following the slump sale of hospital operations to MGM Healthcare in FY24, the company has ceased to have any business operations with no visibility of starting new operations. The management is evaluating corporate restructuring options, and the company holds ~Rs 3,251.64 lakhs in cash and bank balances to meet obligations. The company continues to contest contingent liabilities including medico-legal cases (~Rs 649.40 lakhs), VAT appeals (~Rs 254.93 lakhs), GST appeal (~Rs 22.23 lakhs), and income tax appeal (~Rs 171.43 lakhs). The long-pending Malar Open Offer by IHH Healthcare was finally completed on Nov 10, 2025 at a revised price of Rs 17.60 per share (down from the original Rs 60.10).
This is a significant red flag for shareholders — the company is effectively a non-operating shell after selling its hospital business, and its future depends on a corporate restructuring plan that has not been finalised. While the auditor gave an unmodified opinion, the emphasis on going concern means the stock carries existential uncertainty, and positive-looking Q3 numbers (driven mainly by one-time write-backs) do not reflect ongoing business health. Investors should watch for the restructuring announcement closely.